Survival of Spinal Metastasis Disease based on Immunohistochemistry Subtype of Breast Cancer: A Systematic Review and Meta-analysis

Ivan Hugo Hadisaputra; Tjokorda Gde Bagus Mahadewa; Putu Eka Mardhika

doi:10.3889/oamjms.2021.5786

Authors

Ivan Hugo Hadisaputra Department of Surgery, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia https://orcid.org/0000-0001-6853-4576
Tjokorda Gde Bagus Mahadewa Department of Surgery, Division of Neurosurgery, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia
Putu Eka Mardhika Department of Surgery, Division of Neurosurgery, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.5786

Keywords:

Breast cancer, Human epidermal growth factor 2 type, Luminal A, Luminal B, Spinal metastasis, Triple-negative

Abstract

BACKGROUND: Breast cancer is categorized as a slow-growth tumor in the spinal metastases disease (SMD) scoring system. Based on immunohistochemistry, breast cancer has four subtypes: Luminal A (LumA), luminal B (LumB), human epidermal growth factor 2 (Her-2) type, and triple-negative breast cancer (TNBC). TNBC has the poorest prognosis.

AIM: This study aimed to describe the survival time of breast cancer with SMD based on immunohistochemistry subtypes through systematic review and meta-analysis.

METHODS: This is a systematic review and meta-analysis study. This study used electronic articles published in PubMed and CENTRAL online database. We used keywords ([breast] AND [cancer] AND [spine] AND [metastasis]) to find eligible studies. Articles included were full-text studies in English. Survival time as the outcome was pooled according to the immunohistochemistry subtype of breast cancer. Statistical analysis was performed using software Stata.

RESULTS: Five articles met our inclusion and exclusion criteria. LumA, LumB, Her-2 type, and TNBC have a survival time of 32.84 months, 35.20 months, 60.8 months, and 14.27 months, respectively.

CONCLUSION: TNBC has the lowest survival time in the pooled analysis. We proposed TNBC be categorized as a moderate growth primary tumor.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Adler D, Pepke W, Akbar M. Operative treatment of metastatic breast cancer in the spine with regard to molecular phenotypes. J Cancer Metastasis Treat. 2019;5:45. https://doi.org/10.20517/2394-4722.2019.03 DOI: https://doi.org/10.20517/2394-4722.2019.03

Foerster R, Bruckner T, Bostel T, Schlampp I, Debus J, Rief H. Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer. Radiat Oncol. 2015;10:144. https://doi.org/10.1186/s13014-015-0458-9 PMid:26169373 DOI: https://doi.org/10.1186/s13014-015-0458-9

Bollen L, Wibmer C, Wang M, van der Linden YM, Leithner A, Bunger CE, et al. Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases. Clin Exp Metastasis. 2015;32(1):1-5. https://doi.org/10.1007/s10585-014-9685-y PMid:25359620 DOI: https://doi.org/10.1007/s10585-014-9685-y

Chan-Seng E, Charissoux M, Larbi A, Tetreau R, Gerber YN, Verbizier-Lonjon DD, et al. Spinal metastases in breast cancer: Single center experience. World Neurosurg. 2014;82(6):1344 50. https://doi.org/10.1016/j.wneu.2014.08.010 PMid:25118060 DOI: https://doi.org/10.1016/j.wneu.2014.08.010

Ju DG, Yurter A, Gokaslan ZL, Sciubba DM. Diagnosis and surgical management of breast cancer metastatic to the spine. World J Clin Oncol. 2014;5(3):263-71. PMid:25114843 DOI: https://doi.org/10.5306/wjco.v5.i3.263

Lin J, Goldstein L, Nesbit A, Chen MY. Influence of hormone receptor status on spinal metastatic lesions in patients with breast cancer. World Neurosurg. 2016;85:42-8. https://doi.org/10.1016/j.wneu.2015.07.068 PMid:26260940 DOI: https://doi.org/10.1016/j.wneu.2015.07.068

Wang M, Jensen AB, Morgen SS, Wu CS, Sun M, Li H, et al. Survival analysis of breast cancer subtypes in patients with spinal metastases. Spine (Phila Pa 1976). 2014;39(19):1620-7. https://doi.org/10.1097/brs.0000000000000473 PMid:24979144 DOI: https://doi.org/10.1097/BRS.0000000000000473

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279. https://doi.org/10.1371/journal.pmed.1000279 PMid:20520800 DOI: https://doi.org/10.1371/journal.pmed.1000279

Tokuhashi Y, Uei H, Oshima M, Ajiro Y. Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop. 2014;5(3):262-71. https://doi.org/10.5312/wjo.v5.i3.262 PMid:25035829 DOI: https://doi.org/10.5312/wjo.v5.i3.262

Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 2005;30(19):2186-91. https://doi.org/10.1097/01.brs.0000180401.06919.a5 PMid:16205345 DOI: https://doi.org/10.1097/01.brs.0000180401.06919.a5

Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001;26(3):298-306. https://doi.org/10.1097/00007632-200102010-00016 PMid:11224867 DOI: https://doi.org/10.1097/00007632-200102010-00016

Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthop Scand. 1995;66(2):143-6. https://doi.org/10.3109/17453679508995508 PMid:7740944 DOI: https://doi.org/10.3109/17453679508995508

van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW. Prediction of survival in patients with metastases in the spinal column: Results based on a randomized trial of radiotherapy. Cancer. 2005;103(2):320-8. https://doi.org/10.1002/cncr.20756 PMid:15593360 DOI: https://doi.org/10.1002/cncr.20756

Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br. 2005;87(5):698 703. https://doi.org/10.1302/0301-620x.87b5.15185 PMid:15855375 DOI: https://doi.org/10.1302/0301-620X.87B5.15185

Amelot A, Terrier LM, Cristini J, Buffenoir K, Pascal Moussellard H, Carpentier A, et al. Survival in breast cancer patients with spine metastases: Prognostic assessment involving molecular markers. Eur J Surg Oncol. 2020;46(6):1021-7. https://doi.org/10.1016/j.ejso.2019.12.026 PMid:31899046 DOI: https://doi.org/10.1016/j.ejso.2019.12.026

Tan KA, Tan JH, Zaw AS, Tan JY, Hey HW, Kumar N. Evaluation of prognostic factors and proposed changes to the modified Tokuhashi score in patients with spinal metastases from breast cancer. Spine (Phila Pa 1976). 2018;43(7):512-9. https://doi.org/10.1097/brs.0000000000002350 PMid:28749856 DOI: https://doi.org/10.1097/BRS.0000000000002350

Morgen SS, Fruergaard S, Gehrchen M, Bjørck S, Engelholm SA, Dahl B. A revision of the Tokuhashi revised score improves the prognostic ability in patients with metastatic spinal cord compression. J Cancer Res Clin Oncol. 2018;144(1):33-8. https://doi.org/10.1007/s00432-017-2519-y PMid:28986702 DOI: https://doi.org/10.1007/s00432-017-2519-y

Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106-16. PMid:26175926

Sciubba DM, Goodwin CR, Yurter A, Ju D, Gokaslan ZL, Fisher C, et al. A systematic review of clinical outcomes and prognostic factors for patients undergoing surgery for spinal metastases secondary to breast cancer. Global Spine J. 2016;6(5):482-96. https://doi.org/10.1055/s-0035-1554402 PMid:27433433 DOI: https://doi.org/10.1055/s-0035-1554402

Zadnik PL, Hwang L, Ju DG, Groves ML, Sui J, Yurter A, et al. Prolonged survival following aggressive treatment for metastatic breast cancer in the spine. Clin Exp Metastasis. 2014;31(1):47- 55. https://doi.org/10.1007/s10585-013-9608-3 PMid:23999761 DOI: https://doi.org/10.1007/s10585-013-9608-3